SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a...
A pending or ongoing lawsuit isn't always a reliable indicator of stocks to sell, but, in many cases, investors should take litigation as a sign to dig beneath the surface. I'd first caution retail investors not to take pending litigation as a sure sign of failure or risk; tons of legal firms push frivolous lawsuits in a bid to maximize their own income.
Smart money is looking for the exit as market conditions become increasingly shaky and, more often than not, they're looking at tech stocks to sell more than any other segment or sector. June's net tech stock sales are about to hit their highest monthly level since 2017 as hedge funds and institutional investors begin looking for an off-ramp from increasingly concentrated tech portfolios and in...
The cost of prescription medications in the U.S. has increased by 37% since 2014, far surpassing the rate of inflation, according to data from drug savings company GoodRx. Though the price increases have slowed this year in comparison with the past decade, the average American spends $16.26 out of pocket per prescription, according to the data.
GoodRx aims to give consumers a better handle on prescription affordability. The prescription savings platform introduced its Prescription Cost Tracker to monitor out-of-pocket prescription spending trends in the United States, according to a Wednesday (June 26) press release.
SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., debuted its new Prescription Cost Tracker where it will monitor out-of-pocket prescription spending trends in the U.S. to help Americans better understand prescription affordability and price transparency. Helping Americans get the healthcare they need starts with tackling...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) and reminds investors of the June 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.